Rigel loses Lilly alliance in pharma industry's latest RIPK exit

RIPK1 is becoming a relative desert for large drugmakers. Eli Lilly has joined the exodus, ripping apart the remainder of its up to $960 million partnership with Rigel Pharmaceuticals. The move comes ...